Baczol Expectorant

Product NDC
49523-501
11-digit product format
495230501
Labeler code
49523
Product ID
49523-501_c612d118-b698-45ab-e053-2a95a90a2948
Type
HUMAN OTC DRUG
Nonproprietary name
GUAIFENESIN and PHENYLEPHRINE HYDROCHLORIDE
Dosage form
LIQUID
Route
ORAL
Labeler
Lex Inc
Application
part341
Marketing category
OTC MONOGRAPH FINAL
Marketing start
2013-02-04
Marketing end
0000-00-00
Substance
GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
Active strength
200 mg/5mL; mg/5mL
NDC exclude flag
No
Listing certified through
2022-12-31
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct49523-501DDiscontinued by firm2026-10-05
excluded packagepackage49523-50149523-501-04DDiscontinued by firm2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 30 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source dateDatasetScopePackage NDCCodeStatusSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05excluded productproductDDiscontinued by firmd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage49523-501-04DDiscontinued by firmd630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26excluded productproductDDiscontinued by firmf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage49523-501-04DDiscontinued by firmf5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-31excluded productproductDDiscontinued by firm2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage49523-501-04DDiscontinued by firm2ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28excluded productproductDDiscontinued by firma1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage49523-501-04DDiscontinued by firma1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21excluded productproductDDiscontinued by firmcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage49523-501-04DDiscontinued by firmcfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10excluded productproductDDiscontinued by firmcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage49523-501-04DDiscontinued by firmcdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31excluded productproductDDiscontinued by firm302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage49523-501-04DDiscontinued by firm302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20excluded productproductDDiscontinued by firmed331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage49523-501-04DDiscontinued by firmed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-10excluded productproductDDiscontinued by firm0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage49523-501-04DDiscontinued by firm0efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08excluded productproductDDiscontinued by firmad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage49523-501-04DDiscontinued by firmad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03excluded productproductDDiscontinued by firm367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage49523-501-04DDiscontinued by firm367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09excluded productproductDDiscontinued by firm557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage49523-501-04DDiscontinued by firm557ba5c1ecfa…9c80585c8c6e…
2020-12-18 03:04 UTC · source 2020-12-17excluded productproductIInactivated by FDAe2bbac7714bc…27bdfed8d636…
2020-12-18 03:04 UTC · source 2020-12-17excluded packagepackage49523-501-04IInactivated by FDAe2bbac7714bc…27bdfed8d636…
2020-06-10 20:45 UTC · source 2020-06-10excluded productproductIInactivated by FDA9bebd1f3094a…5416666fcb17…
2020-06-10 20:45 UTC · source 2020-06-10excluded packagepackage49523-501-04IInactivated by FDA9bebd1f3094a…5416666fcb17…
2019-12-08 06:16 UTC · source 2019-12-05excluded productproductIInactivated by FDA110d247fa046…a55b01930146…
2019-12-08 06:16 UTC · source 2019-12-05excluded packagepackage49523-501-04IInactivated by FDA110d247fa046…a55b01930146…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
49523-501-042021-07-01C16284748780-19855d018-e2f4-cd31-e053-dbdaa90ab51aBaczol ® Expectorant
49523-501-042019-11-27C16284748780-19855d018-e2f4-cd31-e053-dbdaa90ab51aBaczol ® Expectorant

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
GUAIFENESINACTIVE INGREDIENT495W7451VQBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
PHENYLEPHRINE HYDROCHLORIDEACTIVE INGREDIENT04JA59TNSJBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
GUAIFENESINACTIVE MOIETY495W7451VQBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
PHENYLEPHRINEACTIVE MOIETY1WS297W6MVBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QPBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
HYDROGENATED CASTOR OILINACTIVE INGREDIENTZF94AP8MEYBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
MAGNESIUM ALUMINUM SILICATEINACTIVE INGREDIENT6M3P64V0NCBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9TBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V3BACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OHBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU4BACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
SORBITOLINACTIVE INGREDIENT506T60A25RBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
SUCRALOSEINACTIVE INGREDIENT96K6UQ3ZD4BACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JPBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
VANILLININACTIVE INGREDIENTCHI530446XBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
WATERINACTIVE INGREDIENT059QF0KO0RBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1
XANTHAN GUMINACTIVE INGREDIENTTTV12P4NEEBACZOL EXPECTORANT (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) LIQUID [LEX INC]1